<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00868153</url>
  </required_header>
  <id_info>
    <org_study_id>14494</org_study_id>
    <secondary_id>MA0501</secondary_id>
    <nct_id>NCT00868153</nct_id>
  </id_info>
  <brief_title>Mirena in Idiopathic Menorrhagia</brief_title>
  <official_title>Levonorgestrel Releasing Intrauterine Device (Mirena) in Idiopathic Menorrhagia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bayer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open-label, uncontrolled, multi-centre observational study that analyses a
      follow-up of 1600 women with dysfunctional uterine bleeding (idiopathic menorrhagia) over a
      period of one year.The patients evaluated at four visits, beginning with the insertion visit
      and 3, 6 and 12 months after insertion.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2004</start_date>
  <completion_date type="Actual">November 2008</completion_date>
  <primary_completion_date type="Actual">November 2008</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>To evaluate the improvement in the quality of life and the degree of satisfaction of women with idiopathic menorrhagia treated with Mirena</measure>
    <time_frame>At vist 1 and 4</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Information about the pattern of menstrual bleeding recorded in an ongoing way throughout the duration of the study</measure>
    <time_frame>Every visit</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The health-related quality of life questionnaire SF-36 at Visits 1 and 4</measure>
    <time_frame>Visit 1 and 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The user satisfaction as recorded at Visit 4</measure>
    <time_frame>visit 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse reactions recorded in an ongoing way throughout the duration of the study</measure>
    <time_frame>every visit</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Laboratory parameters as measured at Visits 1 and 4</measure>
    <time_frame>visit 1 and 4</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">1125</enrollment>
  <condition>Idiopathic Menorrhagia</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Levonorgestrel IUS (Mirena , BAY86-5028)</intervention_name>
    <description>One group</description>
    <arm_group_label>Group 1</arm_group_label>
  </intervention>
  <biospec_retention>None Retained</biospec_retention>
  <biospec_descr>
    <textblock>
      Serum
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Women diagnosed with idiopathic menorrhagia, age 30-45, BMI 18-34
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Woman diagnosed with idiopathic Menorrhagia according to assessment of the
             investigator and according to international guidelines. These woman should also accept
             to be on contraception during the time period that they have Mirena in situ.

          -  Age limit 30-45

          -  BMI= 18-34

          -  Signed informed consent

        Exclusion Criteria:

          -  Medical conditions featured in the Mirena data sheet (See Appendix 1) that
             contraindicate its use, listed below:

          -  Known or suspected pregnancy; current or recurrent pelvic inflammatory disease;
             infection of the lower genital tract; postpartum endometritis; septic abortion during
             the past three months; cervicitis; cervical dysplasia; uterine or cervical malignancy;
             undiagnosed abnormal uterine bleeding; congenital or acquired abnormality of the
             uterus including fibroids if they distort the uterine cavity; conditions associated
             with increased susceptibility to infections; acute liver disease or liver tumor; known
             hypersensitivity to any of the constituents of the product.

          -  Nulliparity

          -  Consumption of Iron, Antiprostaglandins, hormonal drugs and any medication that could
             effect bleeding should be stopped at least 3 months before the first visit and should
             not be used during the course of the study.

          -  History of diabetes mellitus,cardiovascular disease and thyroid abnormalities

          -  Anticoagulation therapy

          -  Cancer history including breast cancer.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bayer Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Bayer</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Many Locations</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Many Locations</city>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Many Locations</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Many Locations</city>
        <country>Jordan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Many Locations</city>
        <country>Kuwait</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Many Locations</city>
        <country>Pakistan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Many Locations</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Many Locations</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Many Locations</city>
        <country>Saudi Arabia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Many Locations</city>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Many Locations</city>
        <country>Sri Lanka</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Many Locations</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Many Locations</city>
        <country>United Arab Emirates</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Bulgaria</country>
    <country>Croatia</country>
    <country>India</country>
    <country>Jordan</country>
    <country>Kuwait</country>
    <country>Pakistan</country>
    <country>Romania</country>
    <country>Russian Federation</country>
    <country>Saudi Arabia</country>
    <country>Serbia</country>
    <country>Sri Lanka</country>
    <country>Turkey</country>
    <country>United Arab Emirates</country>
  </location_countries>
  <link>
    <url>http://www.fda.gov/cder/drug/DrugSafety/DrugIndex.htm</url>
    <description>Click here and search for drug information provided by the FDA.</description>
  </link>
  <link>
    <url>http://www.fda.gov/medwatch/safety.htm</url>
    <description>Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product.</description>
  </link>
  <verification_date>February 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 23, 2009</study_first_submitted>
  <study_first_submitted_qc>March 23, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 24, 2009</study_first_posted>
  <last_update_submitted>February 16, 2015</last_update_submitted>
  <last_update_submitted_qc>February 16, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 18, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Menorrhagia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Levonorgestrel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

